INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/004051

				<u>_</u>
A.		ATION OF SUBJECT MATTER A61K31/192, 31/695, 45/00, A6	1P25/16, 25/28	
Acc	ording to Inte	ernational Patent Classification (IPC) or to both national	classification and IPC	
B.	FIELDS SE.	ARCHED		
Min		entation searched (classification system followed by cla A61K31/192, 31/695, 45/00, A6		
Doc	Jitsuyo		nt that such documents are included in the tsuyo Shinan Toroku Koho roku Jitsuyo Shinan Koho	e fields searched 1996-2005 1994-2005
Elec		ase consulted during the international search (name of d (STN), MEDLINE (STN), REGISTRY (S		rms used)
C.	DOCUMEN	ITS CONSIDERED TO BE RELEVANT		
С	ategory*	Citation of document, with indication, where app		Relevant to claim No.
	У А	Goodman AB, Pardee AB., 'Evid retinoid transport and functi Alzheimer's disease.', Proc.N 04 March, 2003 (04.03.03), 10 to 2905	on in late onset atl.Acad.Sci.USA.,	1-4,6 5
	Y A	Yamakawa T. et al., 'Retinobe Retinoidal activities of comp trimethylsilyl or trimethylge in human promyelocytic leukem J.Med.Chem., 1990 May, 33(5), 1437	ounds having a rmyl group(s) ia cells HL-60.',	1-4,6 5
×	Further do	cuments are listed in the continuation of Box C.	See patent family annex.	
* "A" "E"	document d to be of part	gories of cited documents: efining the general state of the art which is not considered icular relevance cation or patent but published on or after the international	"T" later document published after the inte date and not in conflict with the applic the principle or theory underlying the i "X" document of particular relevance; the considered novel or cannot be consi-	ation but cited to understand nvention
"L"	cited to esta	which may throw doubts on priority claim(s) or which is ablish the publication date of another citation or other on (as specified)	step when the document is taken alone "Y" document of particular relevance; the considered to involve an inventive	claimed invention cannot be
"O" "P"	document re	eferring to an oral disclosure, use, exhibition or other means ublished prior to the international filing date but later than date claimed	combined with one or more other such being obvious to a person skilled in the "&" document member of the same patent	documents, such combination e art
	08 June	l completion of the international search ∋, 2005 (08.06.05)	Date of mailing of the international sear 21 June, 2005 (21.0	
Nar		ng address of the ISA/ se Patent Office	Authorized officer	· ·· <u></u>
Facsimile No.			Telephone No.	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/004051

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Etchamendy N. et al., Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling., J.Neurosci., 2001 Aug, 21(16), pages 6423 to 6429	1-4
X A	JP 10-338658 A (Hoechst Marion Roussel Ltd.), 22 December, 1998 (22.12.98), Claims; Par. Nos. [0004], [0030], [0133] to [0136] & WO 1998/045242 A1	6 1-5
X Y A	JP 2000-502707 A (Pijon Famashutikaruzu Ltd. Patonashippu), 07 March, 2000 (07.03.00), Claims 5, 20; page 13; table 3 2 & US 5965606 A	6 1,2 3-5
Α	Bourdel-Marchasson I. et al., Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients., Age and Ageing, 2001 May, 30(3), pages 235 to 241	1-6
A	JP 2002-332266 A (Sankyo Co., Ltd.), 22 November, 2002 (22.11.02), Claims & EP 1277729 A1	1-6
A	JP 10-59951 A (Institute of Medicinal Molecular Design Inc.), 03 March, 1998 (03.03.98), Claims; Par. No. [0098] & EP 906907 A1	1-6
A .	WO 2002/028810 A2 (F. HOFFMANN-LA ROCHE AG), 11 April, 2002 (11.04.02), Claims; page 137 & JP 2004-510728 A	1-6
A	WO 2002/026727 A2 (ALLERGAN SALES, INC.), 04 April, 2002 (04.04.02), Claims; Par. No. [0003]; table 1 & JP 2004-509955 A	1-6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2005/004051

1) Claims 1 to 3 relate to drugs for accelerating memory fixation which comprise compounds having an aromatic ring and an aromatic carboxylic acid or a tropolone unit. However, it appears that only a small number of specific compounds described in the description are disclosed as being useful for the purpose in the meaning within PCT Article 5 and, therefore, these claims are not supported in the meaning within PCT Article 6.

- 2) In particular, the description discloses no particular case where such a compound has a tropolone unit.
- 3) Claim 3 relates to drugs which contain any compounds having an aromatic ring and an aromatic carboxylic acid or a tropolone unit and having a desired property of being a retinoid binding to RAR subtypes α and β but not binding to γ . However, it appears that only specific compounds described in the description are disclosed in the meaning within PCT Article 5 and, therefore, the claim is not supported in the meaning within PCT Article 6. Even though the common technical knowledge is taken into consideration, it cannot be immediately understood what compounds have the above properties. Thus, it forces to a person skilled in the art to bear a large amount of burden beyond the reasonable extent to confirm whether or not each of an extremely large number of compounds involved in the above compounds has such properties and is efficacious in treating memory fixation failure. Namely, this invention is unclear from this viewpoint.